In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer

British Journal of Cancer

Volumn 86, Issue 10, 2002, Pages 1652-1657

  Aird, R E ^a   Cummings, J ^a   Ritchie, A A ^a   Muir, M ^a   Jodrell, D I ^a   Morris, R E ^b   Chen, H ^b   Sadler, P J ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Drug resistance; Organometallic arene complexes; Ovarian xenografts; Ruthenium(II); Structure activity relationships

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; HC 11; HC 29; ORGANOMETALLIC COMPOUND; RM 175; RMI 175; RUTHENIUM COMPLEX; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CHEMICAL STRUCTURE; COMPLEX FORMATION; CONTROLLED STUDY; CROSS RESISTANCE; DNA DAMAGE; DNA REPAIR; FEMALE; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; AZACITIDINE; CALCIUM CHANNEL BLOCKERS; CARBOPLATIN; CISPLATIN; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; EDETIC ACID; FEMALE; HUMANS; LIGANDS; MICE; MICE, NUDE; NEOPLASM PROTEINS; ORGANOMETALLIC COMPOUNDS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; RUTHENIUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; VERAPAMIL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037141471     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600290     Document Type: Article

References (39)

1. Ruthenium in medicine: Current clinical uses and future prospects
2. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance
3. Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumour cells
4. Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in rats
5. A family of drug transporters: The multidrug resistance-associated proteins
6. Increased accumulation of p53 protein in cisplatin-resistant ovarian cancer cell lines
7. Hmlh1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents
8. Non-platinum chemotherapeutic metallopharmaceuticals
9. Anti-leukaemic action of RuCl2 (DMSO)4 isomers and prevention of brain involvement on P388 leukaemia and on P388/DDP subline
10. Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance
11. Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug sensitive and drug resistant human ovarian cancer cell lines determined by HPLC
12. The Biochemistry of P-glycoprotein-mediated multidrug resistance
13. The role of DNA mismatch repair in drug resistance
14. New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumour cells
15. DNA as a possible target for antitumour ruthenium(III) complexes
16. Clinical perspective on platinum resistance
17. Biochemistry of multidrug resistance mediated by the multidrug transporter
18. Metals in Medicine
19. The human multidrug resistance-associated protein (MRP) gene family: From biological function to drug molecular design
20. Structure, recognition and processing of cisplatin-DNA adducts
21. Recent insights into platinum drug resistance in cancer
22. New developments and approaches in the platinum arena
23. Meeting report on 8th international symposium on platinum and other metal coordination compounds in cancer chemotherapy
24. Preclinical perspective on platinum resistance
25. Synthesis and antitumour activity of triazolium-bis(triazole)-tetrachlororuthenate (III) and bistriazolium-triazolepentachlororuthenate (III). Two representatives of a new class of inorganic antitumour agents
26. Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cells
27. Preclinical phase II studies in human tumour xenografts
28. Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines
29. Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors
30. Inhibition of cancer cell growth by ruthenium arene complexes
31. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter
32. Reversal of adriamycin resistance by verapamil in human ovarian cancer
33. Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins
34. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: A comparison
35. Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats
36. Requirement for ERK activation in cisplatin-induced apoptosis
37. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia
38. Chemoresistance in rat ovarian tumours
39. Transport of amphipathic anions by human multidrug resistance protein 3